Cutia Therapeutics Intrinsic Valuation and Fundamental Analysis - Cutia Therapeutics - Alpha Spread
C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 14.06 HKD -0.28% Market Closed
Market Cap: 4.3B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

Intrinsic Value

Cutia Therapeutics's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one Cutia Therapeutics stock under the Base Case scenario is 16.95 HKD. Compared to the current market price of 14.06 HKD, Cutia Therapeutics is Undervalued by 17%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
16.95 HKD
Undervaluation 17%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation Backtest
Cutia Therapeutics

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Cutia Therapeutics cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Cutia Therapeutics?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Cutia Therapeutics

Provide an overview of the primary business activities
of Cutia Therapeutics.

What unique competitive advantages
does Cutia Therapeutics hold over its rivals?

What risks and challenges
does Cutia Therapeutics face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cutia Therapeutics.

Provide P/S
for Cutia Therapeutics.

Provide P/E
for Cutia Therapeutics.

Provide P/OCF
for Cutia Therapeutics.

Provide P/FCFE
for Cutia Therapeutics.

Provide P/B
for Cutia Therapeutics.

Provide EV/S
for Cutia Therapeutics.

Provide EV/GP
for Cutia Therapeutics.

Provide EV/EBITDA
for Cutia Therapeutics.

Provide EV/EBIT
for Cutia Therapeutics.

Provide EV/OCF
for Cutia Therapeutics.

Provide EV/FCFF
for Cutia Therapeutics.

Provide EV/IC
for Cutia Therapeutics.

Show me price targets
for Cutia Therapeutics made by professional analysts.

What are the Revenue projections
for Cutia Therapeutics?

How accurate were the past Revenue estimates
for Cutia Therapeutics?

What are the Net Income projections
for Cutia Therapeutics?

How accurate were the past Net Income estimates
for Cutia Therapeutics?

What are the EPS projections
for Cutia Therapeutics?

How accurate were the past EPS estimates
for Cutia Therapeutics?

What are the EBIT projections
for Cutia Therapeutics?

How accurate were the past EBIT estimates
for Cutia Therapeutics?

Compare the revenue forecasts
for Cutia Therapeutics with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cutia Therapeutics and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cutia Therapeutics against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cutia Therapeutics compared to its peers.

Compare the P/E ratios
of Cutia Therapeutics against its peers.

Discuss the investment returns and shareholder value creation
comparing Cutia Therapeutics with its peers.

Analyze the financial leverage
of Cutia Therapeutics compared to its main competitors.

Show all profitability ratios
for Cutia Therapeutics.

Provide ROE
for Cutia Therapeutics.

Provide ROA
for Cutia Therapeutics.

Provide ROIC
for Cutia Therapeutics.

Provide ROCE
for Cutia Therapeutics.

Provide Gross Margin
for Cutia Therapeutics.

Provide Operating Margin
for Cutia Therapeutics.

Provide Net Margin
for Cutia Therapeutics.

Provide FCF Margin
for Cutia Therapeutics.

Show all solvency ratios
for Cutia Therapeutics.

Provide D/E Ratio
for Cutia Therapeutics.

Provide D/A Ratio
for Cutia Therapeutics.

Provide Interest Coverage Ratio
for Cutia Therapeutics.

Provide Altman Z-Score Ratio
for Cutia Therapeutics.

Provide Quick Ratio
for Cutia Therapeutics.

Provide Current Ratio
for Cutia Therapeutics.

Provide Cash Ratio
for Cutia Therapeutics.

What is the historical Revenue growth
over the last 5 years for Cutia Therapeutics?

What is the historical Net Income growth
over the last 5 years for Cutia Therapeutics?

What is the current Free Cash Flow
of Cutia Therapeutics?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cutia Therapeutics.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Cutia Therapeutics

Balance Sheet Decomposition
Cutia Therapeutics

Current Assets 1.2B
Cash & Short-Term Investments 1B
Receivables 54.6m
Other Current Assets 116.4m
Non-Current Assets 297.7m
PP&E 223.4m
Intangibles 8.2m
Other Non-Current Assets 66.1m
Current Liabilities 237.8m
Accounts Payable 55.4m
Other Current Liabilities 182.4m
Non-Current Liabilities 81.7m
Long-Term Debt 81.7m
Efficiency

Earnings Waterfall
Cutia Therapeutics

Revenue
198.9m CNY
Cost of Revenue
-98.8m CNY
Gross Profit
100.1m CNY
Operating Expenses
-627m CNY
Operating Income
-526.9m CNY
Other Expenses
2.6m CNY
Net Income
-524.3m CNY

Free Cash Flow Analysis
Cutia Therapeutics

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Cutia Therapeutics's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
Negative Operating Income
Negative Net Income
27/100
Profitability
Score

Cutia Therapeutics's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Cutia Therapeutics's solvency score is 82/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
82/100
Solvency
Score

Cutia Therapeutics's solvency score is 82/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Cutia Therapeutics

Wall Street analysts forecast Cutia Therapeutics stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 12.17 HKD with a low forecast of 9.7 HKD and a high forecast of 15.96 HKD.

Lowest
Price Target
9.7 HKD
31% Downside
Average
Price Target
12.17 HKD
13% Downside
Highest
Price Target
15.96 HKD
14% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Cutia Therapeutics?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for Cutia Therapeutics is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about Cutia Therapeutics dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

Price
Cutia Therapeutics

1M 1M
+59%
6M 6M
+76%
1Y 1Y
-38%
3Y 3Y
-36%
5Y 5Y
-36%
10Y 10Y
-36%
Annual Price Range
14.06
52w Low
5.7
52w High
22.8
Price Metrics
Average Annual Return
N/A
Standard Deviation of Annual Returns
N/A
Max Drawdown -82%
Shares Statistics
Market Capitalization 4.3B HKD
Shares Outstanding 304 024 000
Percentage of Shares Shorted
N/A

Competitive Landscape

Profile

Cutia Therapeutics

Country

China

Industry

Biotechnology

Market Cap

4.3B HKD

Dividend Yield

0%

Description

Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.

Contact

SHANGHAI
Shanghai
20/F, Huanzhi Building, 436 Heng Feng Road, Jingan District
www.cutiatx.com

IPO

2023-06-12

Employees

175

Officers

See Also

Discover More
What is the Intrinsic Value of one Cutia Therapeutics stock?

The intrinsic value of one Cutia Therapeutics stock under the Base Case scenario is 16.95 HKD.

Is Cutia Therapeutics stock undervalued or overvalued?

Compared to the current market price of 14.06 HKD, Cutia Therapeutics is Undervalued by 17%.

Back to Top